Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 278

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 278
---
 following table indicates the impact of foreign currency exchange risk on net working capital as of October 31, 2024. The table below also provides a sensitivity analysis of a 10% strengthening of the foreign currency against functional currencies identified which would have increased (decreased) the Company’s net loss by the amounts shown in the table below. A 10% weakening of the foreign currency against the functional currencies would have had the equal but opposite effect as of October 31, 2024.

| Cash and cash equivalents                                           |     | $ |  137,666 |   |
| Amounts receivable                                                  |     |   |   49,038 |   |
| Accounts payable and accrued liabilities                            |     |   | (192,971 | ) |
| Due to related parties                                              |     |   |  (38,962 | ) |
| Total foreign currency financial assets and                         
 liabilities                                                         |     | $ |  (45,229 | ) |
| Impact of a 10% strengthening or weakening of foreign exchange rate |     | $ |   (4,523 | ) |

| d. | Interest Rate Risk |

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The fair value of the derivative warrant liabilities can fluctuate depending on the fluctuation in the risk-free interest rate.

| e. | Liquidity Risk |

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company’s objective to managing liquidity risk is to ensure that it has sufficient liquidity available to meet its liabilities when due. The Company relies on raising debt or equity financing in a timely manner.

The following amounts are the contractual maturities of financial liabilities as of October 31, 2024 and 2023:

| October 31, 2024                         |     | Total |         |     | Within 
 1 year |         |     | Within    
 2-5 years |        |
|:-----------------------------------------|:----|:------|--------:|:----|:-------|--------:|:----|:----------|-------:|
| Accounts payable and accrued liabilities |     | $     | 526,056 |     | $      | 526,056 |     | $         |      – |
| Due to related parties                   |     |       |  48,962 |     |        |  48,